Delving into the Latest Updates on Lutetium Dotatate LU-177 with Synapse

Overview

Basic Info

Drug Type

Peptide Conjugate Radionuclide, Therapeutic radiopharmaceuticals

Synonyms

177Lu-DOTA0-Tyr3-Octreotate, [Lu-177]-Dota-Tyr3-Octreotate, [Lu-177]-DOTATATE(Advanced Accelerator Applications SA)

+ [15]

Target

SSTR2

Action

antagonists

Mechanism

SSTR2 antagonists(Somatostatin receptor 2 antagonists)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [5]

Active Indication

Somatostatin Receptor-Positive Neuroendocrine TumorSSTR positive Gastro-Enteropancreatic Neuroendocrine TumorGastro-Enteropancreatic Neuroendocrine Tumor+ [17]

Inactive Indication

Carcinoid Heart DiseaseCarcinoid Tumors, IntestinalLiver metastases+ [1]

Originator Organization

Advanced Accelerator Applications SA

Active Organization

Sinotau Pharmaceutical Group

Novartis Pharmaceuticals Corp.

Novartis Pharmaceuticals Canada, Inc.

+ [10]

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

European Union (26 Sep 2017),

SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor

RegulationFast Track (United States), Orphan Drug (South Korea)

Login to view timeline

Structure/Sequence

Molecular FormulaC65H86LuN14O19S2

InChIKeyMXDPZUIOZWKRAA-PRDSJKGBSA-J

CAS Registry753443-19-5

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

Sequence Code 527053030

Source: *****

This phase II trial investigates how well 177Lu-DOTATATE works in treating patients with breast cancer that is stage IV or has come back (recurrent). 177Lu-DOTATATE may shrink or destroy the tumor or circulating breast cancer stem cells if they show evidence of the SSTR2. 177Lu-DOTATATE is a targeted therapy that uses DOTATATE, linked to a radioactive agent called 177Lu. DOTATATE attaches to tumor cells with SSTR2 and delivers 177Lu to kill them. Giving 177Lu-DOTATATE may help decrease the number and size of tumors and the number of circulating cancer stem cells in patient's blood for the treatment of patients with breast cancer positive for SSTR2.

Start Date01 Jan 2025

Sponsor / Collaborator

OHSU Knight Cancer Institute

[+3]

NCT06663072

/ RecruitingPhase 1IIT

A Phase I Study of Fulvestrant in Combination With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.

Start Date13 Dec 2024

Sponsor / Collaborator

The University of Chicago

100 Clinical Results associated with Lutetium Dotatate LU-177

Login to view more data

100 Translational Medicine associated with Lutetium Dotatate LU-177

Login to view more data

100 Patents (Medical) associated with Lutetium Dotatate LU-177

Login to view more data

954

Literatures (Medical) associated with Lutetium Dotatate LU-177

16 Apr 2025·BIOCONJUGATE CHEMISTRY

Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr

Article

Author: Orlov, Grigory A. ; Prach, Anastasia ; Plotnikov, Evgenii ; Bodenko, Vitalina ; Grishin, Yuri K. ; Beloglazkina, Elena K. ; Grigoriev, Gleb P. ; Zyk, Nikolay Y. ; Roznyatovsky, Vitaly A. ; Machulkin, Aleksei E. ; Larkina, Mariia S. ; Beloglazkina, Maria A. ; Petrov, Stanislav A. ; Petrova, Juliana V. ; Varvashenya, Ruslan ; Yusubov, Mekhman S.

Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26^x and its HBV conjugate with DOTA 27, the complete signal assignment in ¹H, ¹³C, and ¹⁵N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the K_D and B_max using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines.

01 Apr 2025·CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Generalized Seizure as an Acute post-[¹⁷⁷Lu]Lu-DOTATATE Side Effect in a Case of Recurrent Meningioma

Article

Author: Alipour, Abdolmajid ; Yazdani, Babak ; Ghaedian, Tahereh ; Ghaedian, Mehrnaz ; Rakhsha, Abbas

[¹⁷⁷Lu]Lu-DOTATATE is a newly trending acceptable therapy in recurrent/residual meningioma with good safety. However, recognizing any possible side effects in this special population would be helpful for better management and individualization of this useful treatment. Although the seizure has been previously reported in a few cases after [¹⁷⁷Lu]Lu-DOTATATE therapy in recurrent meningioma, the acute onset of seizure in these patients, early after therapeutic radioligand administration, is not reported to the best of our knowledge. This report presents a case with the progression of residual meningioma after previous surgery in 2016 who developed with generalized tonic-clonic seizure, a few hours after administration of 200 mCi [¹⁷⁷Lu]Lu-DOTATATE. The patient was taking prophylactic doses of the lacosamide, although no previous history of seizure was reported.

01 Apr 2025·SUPPORTIVE CARE IN CANCER

Navigating care: understanding cancer patients’ experiences with systemic radionuclide therapy

Article

Author: Griessler, Erich ; Winkler, Florian ; Starkbaum, Johannes ; Thircuir, Solenn

Abstract:

Neuroendocrine tumors (NETs) are widely considered to be a rare disease, often diagnosed at a late stage due to the variety of symptoms. Systemic radionuclide therapy (SRT) with Lutathera (177Lu-Dotatate) is a promising treatment for this disease. However, little is known about patients’ experiences with this approach and the radioactivity involved. Based on seven semi-structured interviews, this qualitative study explores how cancer patients perceive their journey to SRT, and the treatment and care they receive in clinics specialized in the delivery of 177Lu-Dotatate to target tumors. The interviews were conducted in France between 2020 and 2021. Six interviews included patients receiving SRT, and one was held with a patient representative for NETs. Three key themes emerged from the analysis: challenges in accessing SRT, including geographic and institutional barriers; the psychological and social impact of radiation-related isolation; and the role of patient-centered care in fostering trust and well-being. Patients reported difficulties navigating the healthcare system, emotional distress due to isolation during treatment, and the importance of support in mitigating these challenges. These findings highlight the need for increased access to SRT, as well as of patient-centered approaches to the various challenges directly and indirectly associated with SRT.

259

News (Medical) associated with Lutetium Dotatate LU-177

22 Apr 2025

·www.prnewswire.com

SHINE Expands Global Footprint with UAE Distribution Partnership For Cancer-Fighting Isotopes

Strategic agreement with Modawina Medical Company strengthens SHINE's presence in EMEA region and advances access to Ilumira, n.c.a. lutetium 177 JANESVILLE, Wis., April 22, 2025 /PRNewswire/ -- SHINE Technologies, LLC, a nuclear fusion company with a platform of medical isotope products, today announced a strategic distribution partnership with Modawina Medical Company to bring Ilumira, SHINE's non-carrier-added lutetium-177 (n.c.a. Lu-177), to patients in the United Arab Emirates. This first-of-its-kind agreement for SHINE in the UAE extends the company's global reach and reinforces its position as a key supplier of cancer-fighting isotopes across the EMEA region. Strategic partnership to serve Middle East patients Continue Reading MMC will distribute Ilumira to its network of radiopharmaceutical manufacturers and nuclear medicine centers in the UAE. Post this Through this long-term agreement, MMC will distribute Ilumira (Lu-177) to its extensive network of radiopharmaceutical manufacturers and nuclear medicine centers in the UAE, increasing access to this important cancer-fighting isotope. Modawina Medical Company (MMC) is dedicated to equipping healthcare providers across the UAE with advanced medical technologies. Through this long-term agreement, MMC will distribute Ilumira to its extensive network of radiopharmaceutical manufacturers and nuclear medicine centers in the UAE, increasing access to this important cancer-fighting isotope. "We're proud to partner with SHINE to bring its high-quality Ilumira to healthcare providers throughout the UAE," said Ahmed Aboufaroukh, Founder and CEO of MMC. "Our mission has always been to provide cutting-edge medical solutions to the region, and this partnership allows us to address the growing demand for targeted radiotherapies that can transform cancer care." Supporting global growth in precision medicine SHINE produces Ilumira at its Cassiopeia facility in Janesville, Wisconsin, one of the highest-capacity Lu-177 production sites in North America. With the ability to support up to 100,000 doses annually, SHINE's proprietary production process ensures a reliable, high-quality supply of this important isotope, crucial given its 6.7-day half-life and need for rapid distribution. This agreement marks another step in SHINE's mission to make advanced cancer care accessible to more patients around the world. As SHINE continues to expand its global network, strategic partnerships like this one will play a vital role in strengthening the supply chain for medical isotopes and supporting the future of targeted radiopharmaceutical therapies. "The Middle East represents an exciting growth region for advanced cancer therapies, and we're proud to help lead that growth," said Greg Piefer, Founder and CEO of SHINE. "What's most exciting about expanding into the UAE with MMC, a partner with deep relationships with healthcare providers across the region, is the opportunity to deliver breakthrough cancer treatments for patients who may not have had access before." Ilumira is a critical medical isotope used in targeted cancer therapies that precisely delivers radiation to cancer cells while minimizing damage to surrounding healthy tissue. These therapies are gaining global momentum and offer powerful new options for patients with limited alternatives. Recently, the FDA expanded the approved indications for Lu-177-based radiopharmaceuticals in treating metastatic prostate cancer. About SHINE Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility. SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy. Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors. Learn more at About Modawina Medical Company Modawina Medical Company (MMC) was established in 2010 to meet the growing demands of healthcare services in the United Arab Emirates. As a trusted partner of leading global medical equipment manufacturers, MMC provides premium healthcare solutions with exceptional after-sales service. The company's comprehensive product portfolio includes advanced equipment for Radiology, Nuclear Medicine, Surgical Instruments, Medical Oncology, Laboratory and Physiotherapy used in hospitals throughout the region. A private enterprise dedicated to serving healthcare providers across the Middle East, MMC is committed to supplying superior equipment while maintaining the highest standards of patient care. The company continuously expands its product offerings to fulfill market demands, ensuring healthcare facilities have access to the best-known brands in the medical field. Through its commitment to quality and service excellence, MMC continues to support the advancement of healthcare delivery throughout the UAE and beyond. Learn more at SOURCE SHINE Technologies, LLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Radiation Therapy

10 Apr 2025

·www.biopharmadive.com

Amid tariff turmoil, Novartis commits to spending $23B on U.S. manufacturing

Dive Brief:Novartis will substantially expand its U.S. footprint, announcing Thursday plans to spend $23 billion over five years to build six new factories, expand three existing ones and add a new research and development hub.The Swiss drugmaker said its expansion will allow it to manufacture all of the medicine intended for U.S. patients in the country, at a time when President Donald Trumps tariff policies have thrown global trading plans into turmoil. Novartis follows Eli Lilly, Merck & Co. and Johnson & Johnson in rolling out new capital expenditure initiatives as Trump pressures major corporations to bring manufacturing to the U.S.Novartis plan appears to reverse some of the companys recent pullback in the U.S., including closure of an R&D hub in San Diego the announced site of the new U.S. R&D site and shutdown of sites in North Carolina, Colorado, and Illinois. The company has disclosed closure of seven manufacturing sites between 2021 and 2024.Dive Insight:Novartis expansion will substantially boost its capital spending, which has run around $1 billion the past several years. It will also broaden Novartis commercial footprint, adding six new facilities to the 12 it already has. In the U.S., it currently lists its subsidiary headquarters in New Jersey, an R&D hub in Cambridge, Massachusetts, and plants in Indianapolis and New Jersey.Novartis said it will build two new plants to manufacture radiopharmaceuticals like its cancer drugs Pluvicto and Lutathera in Florida and in Texas, as well as expand existing plants in Indianapolis, Millburn, New Jersey, and Carlsbad, California.The sites for four facilities havent been determined yet. Three will make biologic drug substances, products, devices and packages, while the fourth will make chemical drug substances, pills and packaging.Already, Novartis relies on U.S. sites to make some of its most complex medicines, such as cell and gene therapies. With the new investment, it will locate some of its antisense oligonucleotide drug manufacturing in the U.S. for the first time.Novartis will also establish a $1.1 billion biomedical research innovation hub in San Diego. That site is due to open between 2028 and 2029.These investments will enable us to fully bring our supply chain and key technology platforms into the U.S. to support our strong U.S. growth outlook, said CEO Vas Narasimhan, in a statement.He also said the company is well-positioned to adjust to trade disruptions, stating that executives are fully confident in our 2025 guidance, mid- to long-term sales growth outlook and 2027 core margin guidance of 40%+.“Novartis is scheduled to release first quarter 2025 results on April 29. '

Oligonucleotide

09 Apr 2025

·www.fiercepharma.com

CDMO PharmaLogic takes majority stake in Norway's Agilera to boost global radiopharma footprint

PharmaLogic is picking up a majority stake in Norway’s Agilera Pharma to bolster its position as a radiopharmaceutical CDMO. Looking to cement its spot in the burgeoning realm of radiopharmaceuticals, Florida-based contract manufacturer PharmaLogic is moving forward with a nuclear medicine M&A play. PharmaLogic is paying an undisclosed sum to pick up a majority stake in Norway’s Agilera Pharma. The move forms part of the CDMO’s strategy to position itself as the industry's first global contract manufacturer specifically dedicated to radiopharmaceuticals, PharmaLogic said in a press release.Agilera, founded in 2023 as a subsidiary of the Institute for Energy Technology in Norway, produces radiopharmaceutical therapies for patients in the U.S., Europe and Asia. To date, the company has delivered more than 600,000 doses of these advanced medicines, PharmaLogic said in an April 9 press release.Radiopharmaceuticals contain radioactive substances that can be used for diagnostic imaging or to treat diseases such as cancer by delivering radiation to specific areas of the body. The field's popularity has been on the rise in recent years, attracting the attention of major pharma outfits like Novartis, which itself has two approved radiotherapies in Lutathera and Pluvicto. As it stands, Agilera is one of just two CDMOs globally that manufactures radiopharmaceutical therapeutics, PharmaLogic's president, Etienne Montagut, said in a statement. Aside from its early- to clinical-phase contract manufacturing business, Agilera also provides commercial production and distribution services and acts as the national wholesaler for radiopharmaceuticals in Norway, PharmaLogic explained in its release. PharmaLogic added that it plans to invest in expansions of Agilera’s infrastructure and manufacturing footprint to help meet mounting demand for radiopharmaceutical therapeutics around the world.Financial terms of the Agilera deal, which is expected to be finalized by the end of June, weren’t disclosed. “By combining our expertise with Agilera’s industry-leading scale and quality systems, we will be uniquely positioned to offer an end-to-end solution for manufacturing therapeutics at scale and ultimately improve global patient access to these essential treatments," PharmaLogic's Montagut said in the company's release. Globally, the radiopharmaceuticals market was estimated to be worth $6.74 billion in 2024 and is projected to hit $7.51 billion this year. The market is expected to nearly double to $14.4 billion by 2034, according to an analysis by Precedence Research.PharmaLogic, for its part, specializes in contract manufacturing and development services for diagnostic imagining and therapeutic radiopharmaceuticals. In addition to producing radiopharmaceuticals, PharmaLogic also manages a distribution network of compounding pharmacies across the U.S. that handle radioactive drugs, which is key given the therapies' short shelf-life.

Radiation Therapy

100 Deals associated with Lutetium Dotatate LU-177

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V10XX04	DB13985

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Somatostatin Receptor-Positive Neuroendocrine Tumor	Japan	Novartis Pharma KK	23 Jun 2021
Somatostatin Receptor-Positive Neuroendocrine Tumor	Japan	FUJIFILM Toyama Chemical Co., Ltd.	23 Jun 2021
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	European Union	Advanced Accelerator Applications SA	26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Iceland	Advanced Accelerator Applications SA	26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Liechtenstein	Advanced Accelerator Applications SA	26 Sep 2017
SSTR positive Gastro-Enteropancreatic Neuroendocrine Tumor	Norway	Advanced Accelerator Applications SA	26 Sep 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gastro-Enteropancreatic Neuroendocrine Tumor	NDA/BLA	United States	Curium Pharma UK Ltd.	09 Jul 2024
Neuroendocrine Tumors	Phase 3	China	Sinotau Pharmaceutical Group	11 Jun 2024
Advanced Neuroendocrine Neoplasm	Phase 3	China	Sinotau Pharmaceutical Group	01 Jun 2024
Advanced Pancreatic Neuroendocrine Tumor	Phase 3	China	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	06 Jul 2023
Carcinoid Tumors, Intestinal	Phase 3	United States	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Belgium	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	France	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Germany	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Italy	Advanced Accelerator Applications SA	06 Sep 2012
Carcinoid Tumors, Intestinal	Phase 3	Portugal	Advanced Accelerator Applications SA	06 Sep 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03972488 (NETTER-2, CTgov)	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	226	30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)+2.5% Lys-Arg sterile amino acid solution+Lutathera (Lutathera® Plus Octreotide LAR 30 mg (Investigational Arm))	irznllqoon(sfkdgipxkm) = yrkjqgkhax oihtntutjt (bhxgbomxsb, tbvpsuefhb - iufjrenqhw) View more	-	10 Oct 2024
NCT03972488 (NETTER-2, CTgov)	Phase 3	Gastro-Enteropancreatic Neuroendocrine Tumor	226	High dose 60 mg octreotide long-acting repeatable (Octreotide LAR 60 mg (Control Arm))	irznllqoon(sfkdgipxkm) = hvjpklsctw oihtntutjt (bhxgbomxsb, gdircafhbq - xbyuvooftk) View more	-	10 Oct 2024
ASTRO2024	Not Applicable	Gastro-Enteropancreatic Neuroendocrine Tumor	-	<sup>177</sup>Lu-DOTATATE	azthcbfewu(zsvscsrzch) = fbxelrmces ozorsgoucq (hreldnvedq )	-	01 Oct 2024
NCT02743741 (OZM-067, ASTRO2024)	Not Applicable	-	33	177Lu-DOTATATE	euxdfvrbno(xfeyqjehwv) = ioboxapgws spuxowpavs (gcvdaavqiw, 0.87) View more	Positive	01 Oct 2024
NCT02743741 (OZM-067, ASTRO2024)	Not Applicable	-	33	68Ga-DOTATATE	euxdfvrbno(xfeyqjehwv) = sfynjmmnco spuxowpavs (gcvdaavqiw, 0.87) View more	Positive	01 Oct 2024
ASTRO2024	Phase 2	Neuroendocrine Tumors	195	177 Lu-DOTATATE (177Lu-D >880 mCi)	xkcmwlnraf(bpjpvmjnio) = ymtbfitnlv wqewugcicz (yqffikvndu, 90 - 100) View more	Negative	01 Oct 2024
ASTRO2024	Phase 2	Neuroendocrine Tumors	195	177 Lu-DOTATATE (177Lu-D 800 Â± 10%)	xkcmwlnraf(bpjpvmjnio) = smyiuejgph wqewugcicz (yqffikvndu, 73 - 100) View more	Negative	01 Oct 2024
ASTRO2024	Phase 2	Meningioma somatostatin receptors	20	177Lu-Dotatate 7.4 GBq	mnjjutwijl(dpbsrjpiky) = ifspuhuuib nfqtgzktog (hdgipbrhcs, 52 - 94) View more	Positive	01 Oct 2024
Biospace Manual	Phase 2	Meningioma	20	Lutathera	adwocmifyl(kcsfwtqqpv) = znyswbyniv blbysbcqqa (xjtssqaipa ) View more	Positive	30 Sep 2024
NETTER-1 (EANM2024)	Not Applicable	177Lu-DOTATATE \| 225Ac-DOTATATE	20	177Lu-DOTATATE	qmkmfpknkl(revbuqcwgj) = vrjurvjhze jkbsmkmgbu (wjuoagkurp, 1.01) View more	Positive	27 Sep 2024
NETTER-1 (EANM2024)	Not Applicable	177Lu-DOTATATE \| 225Ac-DOTATATE	20	225Ac-DOTATATE	qmkmfpknkl(revbuqcwgj) = xandbrpftc jkbsmkmgbu (wjuoagkurp, 0.31) View more	Positive	27 Sep 2024
EANM2024	Not Applicable	Bone metastases	77	177Lu-DOTATATE PRRT	bmheadahcq(wnevnjagpw) = uhrmlpnesl yvjcbqpzpy (rmjqnzuvww ) View more	-	27 Sep 2024
NCT04949282 (SEPTRALU, EANM2024)	Not Applicable	Neuroendocrine Tumors somatostatin receptor (SSTR) overexpressing	-	177Lu-DOTATATE	vwtdvezxxh(xkuiwkohih) = tijgooumww taepcjdwfe (sqwwyzdmcs ) View more	-	27 Sep 2024
EANM2024	Not Applicable	Neuroblastoma	23	Lu-177 DOTATATE	rveksnwhov(nrvurkxatw) = yfuzzurdpf ersajzozst (bsuotmucrg ) View more	Positive	27 Sep 2024

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Lutetium Dotatate LU-177

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation